Pharmaceuticals
Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications
SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and ...
2021-12-03 12:37
5366
Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy
HANGZHOU, China and SHAOXING, China, Dec. 3, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insu...
2021-12-03 12:05
5952
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by the China National Healthcare Security Administration (NHSA). ...
2021-12-03 10:13
2817
Decode Genetics Publishes the Largest Ever Study of the Plasma Proteome
REYKJAVIK, Iceland, Dec. 3, 2021 /PRNewswire/ -- In a study published today in Nature genetics, scientists at deCODE genetics , a subsidiary of the pharmaceutical company Amgen, demonstrate how measuring the levels of a large number of proteins in plasma at population scale when combined with dat...
2021-12-03 03:26
4165
Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH
SHANGHAI, Dec. 2, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on innovative therapies for patients with liver diseases, today announced that it has screened the first patient in theUSA for the RISE study, a Phase IIa clinical trial of HPG18...
2021-12-02 23:00
2123
MingMed Biotechnology Announces U.S. FDA Approval for IND Application of HPK1 Small Molecule Inhibitor PRJ1-3024, and Completion of Phase I Clinical Trials for Dry AMD Treatment Drug QA102
GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing first-in-class pharmaceutical products, announced recently the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for PRJ1-3024, a ...
2021-12-02 22:00
2246
Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics
SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH), are pleased to announce that the companies have entered ...
2021-12-02 21:58
2817
Joint CUHK-HKU study discovers efficacy of COVID-19 vaccines correlates with a probiotic bacterium, Bifidobacterium adolescentis
HONG KONG, Dec. 2, 2021 /PRNewswire/ -- The Centre for Gut Microbiota Research of the Faculty of Medicine at TheChinese University of Hong Kong (CU Medicine) is among the first in the world to discover that germs in our gut (gut microbiota) modulate our immunity and disease severity in COVID-19. ...
2021-12-02 21:00
16754
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women - Results have already led to updated NCCN Guidelines® for breast cancer - New RxPONDER results to be fea...
2021-12-02 16:00
3484
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China
SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration ("NMPA") for marketing in main...
2021-12-02 08:00
4113
Fifty percent recruitment milestone for PROPELLER prostate cancer trial
SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic64...
2021-12-01 21:57
2512
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refrac...
2021-12-01 21:54
2801
Binhai New Area to spearhead China's medical industry development
TIANJIN, China, Nov. 30, 2021 /PRNewswire/ -- Here's a news report from chinadaily.com.cn: By 2025, the Binhai New Area in North China's Tianjin municipality will cultivate industry clusters worth tens of billions of yuan that are dedicated to pharmaceuticals, biotech, medical devices, diagnosti...
2021-12-01 11:20
2431
Sai Life Sciences' pharmaceutical API manufacturing site receives Certificate of Inspection from PMDA, Japan
HYDERABAD, India, Dec. 1, 2021 /PRNewswire/ -- Sai Life Sciences, a leading
global Contract Research, Development & Manufacturing Organization
2021-12-01 09:00
4164
Silexon Partners with Excelra, Deploying GOSTAR to Strengthen its AI-driven Drug Discovery and Biopharmaceutical Research Platform
HYDERABAD, India and NANJING, China, Dec. 1, 2021 /PRNewswire/ -- Excelra, a leading global data & analytics provider, today announced its partnership with Silexon AI Technology, a next-generation biotech company with a scalable AI/ML (Artificial Intelligence and Machine Learning) platform for dr...
2021-12-01 08:05
3951
Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia
SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-...
2021-12-01 08:00
2068
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
HANGZHOU, China, Dec. 1, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced the company has dosed the first patient with LNK01001 in its Phase II clinical trial in subjects with rheumatoid arthri...
2021-12-01 08:00
4698
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
SHANGHAI and CALGARY, Canada, Dec. 1, 2021 /PRNewswire/ -- Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant. Scientists from the two com...
2021-12-01 08:00
3863
Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia
SUZHOU, China, SAN FRANCISCO and ROCKVILLE, Md., Dec. 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and...
2021-12-01 08:00
4371
EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants
PROVIDENCE, R.I., Dec. 1, 2021 /PRNewswire/ -- Today EpiVax, Inc. ("EpiVax") confirmed that the company'sEPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. ("EVT") are also affirming commitment to move the novel T cell epito...
2021-12-01 05:22
2810
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 301 media titles]
2026-09-01 11:00
ViewSonic Launches XG2738-2K-OLED Gaming Monitor with QD-OLED Technology and OLED Care
[Picked up by 288 media titles]
2026-08-27 10:30
RHINOSHIELD AirX Sets GUINNESS WORLD RECORDS™ Title in Record-Breaking Near-Space Drop Challenge
[Picked up by 288 media titles]
2026-08-26 16:08
Most Read
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
16615